42 |
Klinisk Biokemi i Norden · 1 2016
14. Newman DJ, Thakkar H, Edwards RG, Wil-
kie M, White T, Grubb AO, Orice CP. Serum
cystatin C measured by automated immu-
noassay: a more sensitive marker of changes
in GFR than serum creatinine. Kidney Int
1995;47:312-8.
15. Schaeffner ES, Ebert N, Delanaye P, Frei U,
Gaedeke J, Jakob O, et al. Two novel equa-
tions to estimate kidney function in persons
aged 70 years or older. Ann Intern Med
2012;157:471-81.
16. Dharnidharka VR, Kwon C, Stevens G. Serum
cystatin C is superior to serum creatinine as
a marker of kidney function: a meta-analysis.
Am J Kidney Dis 2002;40:221-6.
17. Peralta CA, Shlipak MG, Judd S, Cushman
M, McClellan W, Zakai NA, et al. Detection
of chronic kidney disease with creatinine,
cystatin C, and urine albumin-to-creatinine
ratio and association with progression to
end-stage renal disease and mortality. JAMA
2011;305:1545-52.
18. Inker LA, Schmid CH, Tighiouart H, et al.
Estimating glomerular filtration rate from
serum creatinine and cystatin C. N Engl J
Med 2012;367:20-9.
19. Vinge E, Lindergard B, Nilsson-Ehle P, Grubb
A. Relationships among serum cystatin C,
serum creatinine, lean tissue mass and glome-
rular filtration rate in healthy adults. Scand J
Clin Lab Invest 1999;59:587-92.
20. Finney H, Newman DJ, Price CP. Adult refe-
rence ranges for serum cystatin C, creatinine
and predicted creatinine clearance. Ann Clin
Biochem 2000;37 ( Pt 1):49-59.
21. Sarnak MJ, Katz R, Stehman-Breen CO, Fried
LF, Jenny NS, Psaty BM, et al. Cystatin C con-
centration as a risk factor for heart failure in
older adults. Ann Intern Med 2005;142:497-
505.
22. Shlipak MG, Sarnak MJ, Katz R, Fried LF,
Seliger SL, Newman AB, et al. Cystatin C
and the risk of death and cardiovascular
events among elderly persons. N Engl J Med
2005;352:2049-60.
23. Dalrymple LS, Katz R, Kestenbaum B, de
Boer, IH, Fried L, Sarnak MJ, Shlipak MG.
The risk of infection-related hospitalization
with decreased kidney function. Am J Kidney
Dis 2012;59:356-63.
24. Koenig W, Twardella D, Brenner H, Rothen-
bacher D. Plasma concentrations of cystatin
C in patients with coronary heart disease
and risk for secondary cardiovascular events:
more than simply a marker of glomerular fil-
tration rate. Clin Chem 2005;51:321-7.
25. Abrahamson M, Alvarez-Fernandez M, Nat-
hanson CM. Cystatins. Biochem Soc Symp
2003:179-99.
26. Bengtsson E, Nilsson J, Jovinge S. Cystatin
C and cathepsins in cardiovascular disease.
Front Biosci 2008;13:5780-6.
27. Svensson-Färbom P, Ohlson Andersson M,
Almgren P, Hedblad B, Engström G, Persson
M, et al. Cystatin C identifies cardiovascular
risk better than creatinine-based estimates
of glomerular filtration in middleaged indi-
viduals without a history of cardiovascular
disease. J Intern Med 2014;275:506-21.
28. Beilby J, Divitini ML, Knuiman MW, Rossi E,
Hung J. Comparison of cystatin C and crea-
tinine as predictors of cardiovascular events
in a community-based elderly population.
Clin Chem 2010;56:799-804.
29. Schöttker B, Herder C, Muller H, Brenner
H, Rothenbacher D. Clinical utility of crea-
tinine- and cystatin C-based definition of
renal function for risk prediction of primary
cardiovascular events in patients with diabe-
tes. Diabetes Care 2012;35:879-86.
30. Angelidis C, Deftereos S, Giannopoulos G,
Anatoliotakis N, Bouras G, Hatzis G, et al.
Cystatin C: an emerging biomarker in car-
diovascular disease. Curr Top Med Chem
2013;13:164-79.
31. Smith GD, Ebrahim S. ‘Mendelian randomi-
zation’: can genetic epidemiology contribute
to understanding environmental determi-
nants of disease? Int J Epidemiol 2003;32:1-22.
32. Dempfle A, Scherag A, Hein R, Beckmann L,
Chang-Claude J, Schafer H. Gene-environ-
ment interactions for complex traits: defini-
tions, methodological requirements and chal-
lenges. Eur J Hum Genet 2008;16:1164-72.
